No. Ozempic is Novo Nordisk’s branded semaglutide. Compounded semaglutide is made by a licensed compounding pharmacy as a sterile injectable using the same active ingredient. Same molecule, different manufacturer, different price, different regulatory pathway. Our compounded vs branded guide breaks down the specifics.

As of April 2026, Mochi and Henry Meds lead on price for compounded semaglutide starting doses, typically in the $149 to $229 per month range. Tirzepatide is higher across all providers. We maintain a live price tracker in the provider comparisons hub, updated every week.

The most common side effects are nausea, vomiting, diarrhea, constipation, and fatigue, especially during dose titration. Less common but serious risks include pancreatitis, gallbladder disease, and thyroid C-cell tumors (boxed warning). Side effects from compounded formulations mirror branded semaglutide when the active ingredient is pharmaceutical grade.

BPC-157 sits in a legal gray zone. It is not FDA approved, was removed from the FDA 503A compounding bulks list, and is commonly sold as a research chemical not for human use. Possession for personal research is generally not prosecuted, but it is not an approved therapeutic and WADA bans it for competing athletes.

The most researched recovery peptides are BPC-157 and TB-500 (thymosin beta-4), often stacked together for soft tissue and tendon recovery. Human evidence is limited; most data comes from animal studies. CJC-1295 and Ipamorelin are commonly stacked for GH secretion. Always consult a clinician and understand that these are not FDA approved for human therapeutic use.

Evidence for NAD+ is early. Small studies and anecdotal reports suggest improvements in energy, cognitive clarity, and metabolic markers, but the category lacks large randomized trials. NAD+ injection and IV therapy are available from compounding pharmacies and med spas; response varies widely. Our NAD+ guide covers what the research actually supports.